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COMMENTARY
AIT (allergen immunotherapy): a model 
for the “precision medicine”
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Abstract 
The interpretation of medical approaches, especially therapy, evolved rapidly in the last century. Starting from the 
simple description of symptoms, we moved to the pathophysiological descriptions, to the evidence-based medicine, 
until the so-called “precision medicine”. This latter can be defined as a structural model aimed at customizing health-
care, with medical decisions/products tailored on an individual patient at a highly detailed level. In this sense, allergen 
immunotherapy represents an optimal model of “precision medicine”, since we know and describe symptoms, 
function, aetiological agents at molecular level, and we have the possibility to intervene on the natural history of the 
disease. If considered under the point of view of pharmaco-economy, that is prescribing the optimal treatment to the 
right patient, allergen immunotherapy represents an almost-ideal model of precision medicine.
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General aspects
The medical science slowly evolved, along centuries, from 
the Hippocratic “humours” [1] to a more pathophysiol-
ogy-oriented interpretation of clinical phenomena [2–4], 
until the current “omic” sciences. Thus, it seems that a 
more and more potent magnifying lens has become avail-
able to study and understand diseases. In addition, it is 
clear that the clinical science, the mechanistic knowledge 
and the translational applications are becoming more and 
more strictly interconnected.
From the clinical point of view (essentially the thera-
peutic aspect), a “blockbuster” approach was applied in 
clinical practice during the last decades. This attitude was 
likely due to a superficial and incomplete knowledge of 
the underlying mechanisms of diseases. The advanced 
insights on the mechanisms and the specific features of 
patients’ groups leaded to the definition of phenotypes 
and endotypes [5, 6]. This “stratification” of groups, in 
turn, provided a more detailed definition of diagnosis 
and treatments, consequently resulting in more appropri-
ate definition of the eligibility of patients to the different 
therapeutic tools. The “phenotype driven therapy” is now 
a real and urging need, especially when expensive drugs, 
such as biologicals/biosimilars have to be prescribed [7, 
8]. This aspect is unavoidably linked to sustainability for 
HealthCare Systems, which will afford relevant economic 
burdens. These latter will grow dramatically targeting, for 
instance, 30 % of Gross Incoming Product in 2040 in the 
US [9]. According to those premises we have to face two 
major reasons for a more selective approach (phenotyp-
ing/endotyping) to the patients who are potentially can-
didates to an effective treatment:
  • medical/scientific aspects
  • pharmaco-economic aspects.
The “blockbuster approach” (i.e. one size fits all) can-
not be currently used with many of the very expensive 
treatments available, where the best cost/effective treat-
ment should be provided. This also implies a greater pro-
fessional and responsible involvement of specialists in 
properly selecting patients. The “precision medicine” can 
be defined as a structural model aimed at customizing 
healthcare at best, with medical decisions, practices, and/
or products tailored on an individual patient. The term of 
“personalized medicine” is also used interchangeably.
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The major goals of “personalized medicine” are essentially:
  • to improve the clinical outcomes and their predict-
ability;
  • to reduce the side effects caused by a possibly inap-
propriate treatment;
  • to increase the quality of life;
  • to encourage patients’ compliance due to a perceived 
clinical improvement;
  • to optimise the use of healthcare resources.
Hamburg and Collins [10], described the path to a per-
sonalized medicine as summarized in Fig.  1, highlight-
ing the relevant economic investments to pursue this 
approach: cost/effective medicine. A pertinent example is 
the identification, in cystic fibrosis, of one of the molec-
ular mechanisms that cause the disease: this is present 
in only 4  % of patients, but once they are identified, an 
effective treatment, although expensive, can be given 
with expected positive results [11]. Another explana-
tory example is the specific antagonism to IL-5 in eosin-
ophilic-driven asthma. Also in this case, it is possible to 
reasonably identify a priori those candidate patients who 
will respond to the targeted biological treatment [12, 13].
Personalized medicine is still a critical aspect in the 
most complex, prevalent and expensive chronic diseases, 
such as COPD [14] or asthma in general [15], where a 
targeted approach would heavily affect the management.
Allergen immunotherapy (AIT)
Allergen immunotherapy remains one of the best candi-
dates to a personalized-medicine approach since we cur-
rently know: (a) the main immunological and molecular 
events underlying the allergic symptoms [16]; (b) which 
are the more specific and sensitive standard diagnos-
tic tests to identify the IgE-mediated reactions; (c) the 
relevant molecules involved in allergic reactions [17, 18]; 
(d) purified and standardized documented products for 
effective and safe AIT.
Under a clinical point of view, AIT is well characterized 
by numerous clinical trials showing the effectiveness of 
the treatment [19–21], and this is even more apparent for 
sublingual immunotherapy (SLIT), for which large trials 
involving hundreds of patients are nowadays available 
[21]. According to this, we can perform an optimized 
prescription (Fig. 2) [17].
Allergen immunotherapy has a unique immunological 
rationale, tailored to the specific IgE spectrum of each 
individual. In addition, AIT can modify the immune 
response against the allergen for which the treatment 
is designed, thus allowing to modify the natural history 
of the disease itself [22], and this is a unique feature in 
treating allergies. In addition, the AIT long term effect 
remains a unique feature of great impact in the phar-
maco-economic evaluation, since no other allergy treat-
ment has this specific characteristic [23].
Nonetheless, we still need biomarkers which could be 
predictive of the expected efficacy and, consequently, the 
identification of the eligible patients, with a direct eco-
nomic implication. We, would highlight other critical 
issues for a correct and effective AIT. Certainly we would 
need a more spread knowledge on molecular allergy, to 
be ourselves more adherent to the definition of person-
alized medicine. Moreover, a clear characterization and 
definition of commercial products for vaccination is also 
urgently needed. A precision medicine requires precision 
approaches, whereas nowadays, for many commercial 
products the characterization remains poor, and in some 
cases an experimental proof of efficacy is lacking [24]. 
This is the reason why, regulatory authorities are strenu-
ously trying to provide clear rules for the marketing, and 
for AIT products commercial authorizations [25, 26].
Conclusion
According to the current knowledge of mechanistic 
aspects, to the detailed identification of aetiological 
agents, and the not negligible longstanding experience, 
AIT, in the context of the other available therapies for res-
piratory allergy, is the most “personalized” treatment [27] 
(Fig. 2). Possibly, in the past, the concept of AIT as Preci-
sion Treatment was not properly considered or empha-
sized, but AIT was and still is upfront in this context. We 
are aware that more precise information and markers will 
be provided by systems medicine [28] and networks pro-
jects [29, 30]: these will further improve AIT indication, 
patient selection for clinical trials, prescription and, con-
sequently, effectiveness and cost/effectiveness.
The area of medical technology is evolving rapidly 
and monitoring data will be critical to many aspects of Fig. 1 The consequential process underlying personalized medicine
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developing AIT as precision medicine: finding patients 
with the required biomarkers (Fig. 3) for trials, monitor-
ing efficacy and safety of targeted therapies will be also 
needed for reaching a justified sustainability. Finally, also 
partnerships between allergy scientific community, man-
ufacturers and all other stakeholders in the healthcare 
system should be promoted and encouraged to achieve 
significant changes in medicine reimbursement.
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Fig. 2 The role of allergen immunotherapy (AIT) as a personalized or precision medicine
Fig. 3 Allergen immunotherapy (AIT): the ideal pathway towards precision medicine
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